Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:20PM CST
Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic weight management.
OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), ARNA: 3.57 (-0.01)
Novo Nordisk Enters Anti-Obesity Space With New FDA Approval
Spencer Osborne - at Seeking Alpha - Wed Dec 24, 6:46AM CST
ZFGN: 30.99 (+0.67), OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
FDA clears Novo Nordisk's weight loss drug Saxenda
AP - Tue Dec 23, 3:49PM CST
NEW YORK (AP) — The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
FDA clears Novo weight management drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:05PM CST
OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 5:10PM CST
The CHMP gave a positive opinion on the approval of Orexigen's (OREX) weight loss drug, Mysimba.
BIIB: 340.89 (+5.13), OREX: 5.98 (+0.01), AMGN: 160.67 (+3.15)
Contrave Prescriptions Still Rising In A Down Week
Clinically Sound Investor - at Seeking Alpha - Mon Dec 22, 2:47PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Orexigen - Contrave Script Numbers Remain Impressive
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:31PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Belviq Scripts Dip - Lack Of T.V. Ads Will Impact Next Numbers
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:27PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Orexigen Retreats After Positive News In Europe: 3 Things To Watch For
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:18PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Orexigen Therapeutics (OREX) Stock: Weak On High Volume Today
at The Street - Mon Dec 22, 9:03AM CST
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a weak on high relative volume candidate
OREX: 5.98 (+0.01)
Buying These 3 Stocks Is Like Making a Bet in a Burning House
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 7:54AM CST
Source: Flickr user Mark Esau Bargain hunters are often attracted to beaten-down biotech stocks because they sometimes rebound in astonishing fashion. That said, it can be extremely difficult to separate the wheat from the chaff when mulling over...
OREX: 5.98 (+0.01), AZN: 70.44 (+0.26), VVUS: 2.99 (-0.02), AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
New Obesity Drug Available Soon
Brian Orelli, The Motley Fool - Motley Fool - Sun Dec 21, 9:22PM CST
Europeans will have a new option for treating their obesity shortly. The Committee for Medicinal Products For Human Use, or CHMP, gave Orexigen 's Mysimba a positive recommendation. Orexigen will have to wait for the European Commission to adopt...
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
Arena And Vivus Investors Need To Grasp Implications Of Orexigen
Spencer Osborne - at Seeking Alpha - Fri Dec 19, 1:22PM CST
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Contrave Wins Approval Recommendation In Europe
Spencer Osborne - at Seeking Alpha - Fri Dec 19, 10:53AM CST
OREX: 5.98 (+0.01)
Biotech Equities Technical Analysis -- Incyte, ZIOPHARM Oncology, Hemispherx Biopharma, Infinity Pharma, and Orexigen Therapeutics
PR Newswire - Fri Dec 19, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Hemispherx Biopharma Inc. (NYSE MKT: HEB), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 18, 2014, rallied as the Dow Jones Industrial Average finished at 17,778.15, up 2.43% and the NASDAQ Composite closed at 4,748.40, up 2.24%. The S&P 500 finished the session 2.40% higher at 2,061.23. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 813.60, up 2.77%, with the index advancing 8.37% in the previous three months. Register for your complimentary reports on these five stocks at:
OREX: 5.98 (+0.01), ZIOP: 4.76 (+0.07), HEB: 0.22 (-0.02), INCY: 71.57 (+1.99), INFI: 16.65 (+0.37)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:11AM CST
KMX: 67.61 (-0.15), MOLG: 2.92 (+0.03), CERS: 6.49 (+0.29), OREX: 5.98 (+0.01), APP: 1.06 (+0.01), ISIS: 59.49 (+1.88), PIR: 15.33 (-0.11), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), FMD: 5.06 (unch), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), NVGN: 2.40 (-0.09), TRXC: 2.79 (+0.03), NQ: 4.32 (-0.36), FINL: 22.79 (+0.17), TNK: 4.74 (+0.04)
Europe advisory committee gives thumbs up to Orexigen obesity med
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:35AM CST
OREX: 5.98 (+0.01)
Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators
at The Street - Fri Dec 19, 7:25AM CST
European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)
Orexigen's Mysimba(TM) (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union
PR Newswire Europe - Fri Dec 19, 6:24AM CST
LA JOLLA, California, Dec. 19, 2014 /PRNewswire/ -- Orexigen Therapeutics announced today that the Committee for Medicinal Products For Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a centralized marketing authorization for Mysimba(TM) (naltrexone HCI / bupropion HCI prolonged release), as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (>=18 years) with an initial Body Mass Index (BMI) of >= 30 kg/m(2) (obese), or >= 27 kg/m(2) to Ee 30 kg/m(2) (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).
OREX: 5.98 (+0.01)